Goldman Sachs has released a research report predicting that Broadcom (AVGO.US) will see its stock price, supported by the excellent performance of its AI semiconductors, rise mildly following the release of its strong quarterly results and market-beating guidance.

In line with upward revisions in capital expenditures by major AI clients, Broadcom's guidance for 2Q26 AI semiconductor revenue is 15% higher than market expectations, indicating continued growth in both XPU and networking businesses.

Goldman Sachs has given Broadcom a Buy rating and a target price of USD450.
~



AAStocks Financial News
Web Site: www.aastocks.com

HONG KONG, March 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II study (COMPASSION-03/AK104-201) of cadonilimab as a monotherapy for patients with recurrent or metastatic cervical cancer (R/M CC) who have failed prior platinum-containing chemotherapy, were presented in a late-breaking oral presentation by Professor Wu Xiaohua from Fudan University Shanghai Cancer Center, the Principal Investigator, at the 27th European Congress on Gynaecological Oncology (ESGO 2026).

The long-term survival data of cadonilimab monotherapy in this patient population confirms cadonilimab's ability to convert deep tumor remission into long-term disease control and survival benefits. This study provides clinically meaningful evidence to support its use in the treatment of advanced cervical cancer, offering patients a new therapeutic option that significantly improves survival outcomes.

Best Overall Response (BOR) Analysis Demonstrates Remarkable Survival Benefit

In the updated data presented at the ESGO Congress, with a median follow-up duration of 26.5 months, a BOR-stratified analysis was conducted in all 99 efficacy-evaluable patients. This analysis further quantified the strong correlation between the depth of tumor response and long-term survival benefit associated with cadonilimab treatment.

Among all subjects who achieved a complete response (CR), the median overall survival (OS) was not reached (NR), with a 24-month OS rate of up to 100.0% (nominal p = 0.0002). The median progression-free survival (PFS) was also not reached, with a 12-month PFS rate of 84.6% (nominal p < 0.0001).

In patients achieving partial response (PR), the median OS remained unreached (NR), with a 24-month OS rate of 63% (nominal p = 0.0002). The median PFS was 11.17 months, and the 12-month PFS rate was 47.3% (nominal p < 0.0001).

The median time to response (mTTR) in the CR patients was 1.84 months, comparable to that observed in the PR patients (1.87 months). The median duration of response (mDoR) in the CR patients was not reached and was significantly longer than that in the PR patients (nominal p = 0.035).

Cadonilimab Provides Sustained Long-Term Survival Benefit Irrespective of PD-L1 Expression Status

The COMPASSION-03 study enrolled more than 18% of patients with PD-L1 CPS < 1, and 36% of participants had received ≥2 prior lines of systemic therapy. Study findings demonstrated that cadonilimab monotherapy achieved a median OS of 17.5 months (11.4, NE).

Updated long-term follow-up data showed durable survival benefit across the overall population, including both PD-L1 positive and PD-L1 negative patients, with 18-month and 24-month OS rates of 47.8% and 40.9%, respectively.

The Rising Value of a Foundational IO 2.0 Backbone

Cadonilimab, the world's first approved cancer immunotherapy bispecific antibody that was commercially launched in 2022, has demonstrated its breakthrough clinical value across a large number of approved indications and Phase III trials. Cadonilimab addresses critical clinical gaps by benefiting cancer patients across all levels of PD-L1 expressions, earning strong recognition from clinicians and patients. Importantly, cadonilimab shows superior efficacy versus current standard of care in challenging settings like immunotherapy-resistant tumors and cold tumors that had limited response to PD-1/L1 agents.

This differentiated profile stems from its dual targeting of PD-1 and CTLA-4 with synergistic anti-tumor activity. This novel mechanism preserves the therapeutic benefits of both targets while overcoming their individual limitations. Specifically, the toxicity that restricts the clinical utility of current CTLA-4 monotherapy agents, and the poor response to PD-1/L1 agents in PD-L1 low/negative populations.

Cadonilimab is now approved for three indications in China: first-line gastric cancer, first-line cervical cancer, and recurrent/metastatic cervical cancer. It is under evaluation in 11 registrational/Phase III studies across major first-line tumor indications, various cold tumors, and IO-resistant settings, including a global Phase III trial in first-line gastric cancer and a global registrational trial in IO-resistant hepatocellular carcinoma.

While advancing cadonilimab's global clinical development independently, Akeso remains committed to open collaboration, integrating premier worldwide resources to accelerate international market access and benefit cancer patients worldwide.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

深圳2026年3月5日 /美通社/ -- 近日，由晶泰科技(2228.HK)孵化的臨床階段免疫代謝創新藥物研發公司——深圳萊芒生物科技有限公司（Leman Biotech Co., Ltd., 以下簡稱 「萊芒生物」）宣佈完成規模近 2 億元的 A 輪新增融資，其管線成果與技術平台潛力持續獲得醫藥領域資深投資人認可與背書。新增投資人包括粵財中垠、礦世之星、Mony Valley、泰瓏投資（泰格醫藥旗下基金管理平台）、中山創投等，晶泰科技與富匯創投作為老股東持續加注支持。

此前，萊芒生物已獲得包括天圖投資、五源資本、富匯創投、君熠資本等頂尖機構投資。此次融資，標誌著生物醫藥領域資深投資機構對萊芒生物全球首創的免疫代謝重編程技術及其臨床價值的持續支持。晶泰科技賦能萊芒生物基於全球首創的免疫代謝重編程技術，開發出極低劑量代謝增強型 CAR-T 細胞療法，僅用 1‰ 於常規 CAR-T 的用藥劑量，在血液瘤、紅斑狼瘡等重大疾病領域實現數十位患者 100% 完全緩解（CR）的突破性進展，能顯著降低動輒「百萬一針」的 CAR-T 療法的成本，為這一昂貴的救命藥納入醫保、人人可及創造可能。本輪資金將重點支持該 CAR-T 細胞藥物註冊 I期臨床研究，加速推進其自動化生產工藝研發與驗證，以及啟動代謝增強型實體瘤細胞治療藥物的臨床轉化。

在晶泰科技的投資孵化與研發賦能下，萊芒生物聚焦創新腫瘤免疫治療藥物管線的研發，開發並持續升級了其獨有的 META 10 與 META 10-AI 兩大 AI+代謝重編程技術平台，實現對耗竭 T 細胞代謝的精準調控，從而顯著增強其增殖能力、細胞殺傷活性及免疫記憶功能。相比傳統 CAR-T 療法成本高昂、響應率低、毒副作用顯著等臨床難題，萊芒生物開發的代謝增強型 CD19 CAR-T 療法，以更低劑量、更低價快速的制備過程，實現更高的臨床響應率和更優的安全性，推動患者達到完全緩解，為安全高效的新一代 「平價」 CAR-T 療法上市乃至進入醫保奠定基礎。

目前，萊芒生物多條管線進入 IIT（研究者發起臨床）階段，適應症涵蓋惡性血液瘤、實體瘤以及自身免疫性疾病等多個具備廣闊治療前景的重大疾病領域，並展現出極強的治療潛力。在復發/難治性淋巴瘤、白血病等適應症中，CD19 CAR-T療法以常規 CAR-T 的 1‰ 劑量，實現 20 餘位患者 100% 完全緩解（CR）。在中重度系統性紅斑狼瘡（SLE）患者中，CD19 CAR-T 同樣實現超低劑量給藥（常規劑量的 1‰），並取得「免清淋」重大突破——患者回輸前無需清淋預處理、亦無需中斷原有治療，經單次輸注後即可實現完全停藥下的DORIS緩解（完全緩解），為 SLE 患者開辟全新治療路徑。在實體瘤領域，代謝增強型腫瘤浸潤淋巴細胞注射液（META 10-TILs）的IIT臨床研究已正式啟動，還有多條針對宮頸癌、肝癌、膽管癌等實體瘤適應症的CAR-T管線正在進入IIT臨床研究階段。

萊芒生物正在中美兩地同步推進多項新藥臨床試驗申報（IND），多個儲備項目亦在高效開展，其中代謝增強型體內 CAR-T（in vivo CAR-T）進入快速迭代期。同時，自主研發的全自動細胞製造系統樣機已初步完成，標誌著公司在規模化、低成本、高一致性產業化道路上邁出關鍵一步。

萊芒生物聯合創始人、董事長唐力教授表示：「感謝新老股東的信任與支持，本次新增融資的完成，將加速公司核心技術落地與管線推進。我們將堅守創新初心，聚焦免疫細胞治療的技術突破與臨床需求，加速推進創新藥物的臨床轉化與產業化，致力於為全球患者提供更高效、更安全、更可及的治療方案。」

關於萊芒生物

深圳萊芒生物科技有限公司（Leman Biotech Co., Ltd）是一家處於臨床階段的免疫代謝創新藥物研發公司，由瑞士洛桑聯邦理工學院（EPFL）唐力教授團隊聯合晶泰科技共同創立。基於免疫代謝重編程（META 10）+前沿人工智能（AI）的創新技術，公司專注於研發代謝增強型腫瘤免疫治療藥物。公司核心技術 META 10 展示出治癒實體腫瘤的巨大潛力，相關成果發表於 Nature、Nature Biotechnology、Nature Immunology 和 Lancet Haematology 等國際頂級學術期刊，並申請了多項 PCT 專利和中國發明專利。2022 年以來，公司累計獲得超 4 億元風險投資和項目資助，榮膺 2025 年全國 「顛覆性技術創新」 大賽最高獎項等數十項生物醫藥領域國家或省市級獎項，併入選國家重點研發計劃「顛覆性技術創新」 重點專項。臨床進展獲美國基因與細胞治療協會（ASGCT 2024）和美國癌症協會（AACR 2024）最新突破性（Late-Breaking）進展口頭報告（全國唯一）。

關於晶泰科技

晶泰科技（「XtalPi Holdings Limited」，股份簡稱：晶泰控股，XTALPI，股票代碼：2228.HK）由三位麻省理工學院的物理學家於 2015 年創立，是一個基於量子物理、以人工智能賦能和機器人驅動的創新型研發平台。公司採用基於量子物理的第一性原理計算、人工智能、高性能雲計算以及可擴展及標準化的機器人自動化相結合的方式，為製藥及材料科學（包括農業技術、能源及新型化學品以及化妝品）等產業的全球和國內公司提供藥物及材料科學研發解決方案及服務。

Broadcom (AVGO.US) has reported that its earnings for 1FQ ending February 1 grew by nearly 34% YoY to USD7.35 billion, while the adjusted EPS came in at USD2.05, slightly above the expected USD2.03.

Hock Tan, Broadcom's CEO, estimated AI chip sales to exceed USD100 billion next year. Stimulated by the news, Broadcom's stock price rose by 5.27% to USD334.25 in after-hours trading.
~



AAStocks Financial News
Web Site: www.aastocks.com

After the market closed on Wednesday, chipmaker Broadcom (AVGO.US) announced that its net profit for 1FQ ended February 1, 2026, increased by nearly 34% YoY to USD7.35 billion, while the adjusted EPS reached USD2.05, slightly above the expected USD2.03.

During the period, Broadcom's revenue beat forecasts with a rise of 29% to USD19.31 billion. In particular, the AI revenue surged by 106% to USD8.4 billion.
~



AAStocks Financial News
Web Site: www.aastocks.com

US stocks elevated on Wednesday, and the surge in oil prices slackened, as the market kept close tabs on the developments in the US-Israel-Iran conflict but the latest US economic data boosted investor sentiment.

The Nasdaq showed the strongest rebound among the three major stock indices, opening up 104 points or 0.5%, and closing up 290 points or 1.3% at 22,807. The S&P 500 added 52 points or 0.8%, closing at 6,869. The DJIA opened up 88 points or 0.2% and briefly turned south, but ended the day up 238 points or 0.5%, at 48,739.

Techs picked up, with Micron Technology (MU.US) and AMD (AMD.US) swelling more than 5%; Intel (INTC.US) leaping about 6%; Broadcom (AVGO.US) and NVIDIA (NVDA.US) both mounting by over 1%.

Amazon (AMZN.US) led the upswing among "Magnificent Seven", up by nearly 4%, while Tesla (TSLA.US) shot up over 3%.

The US will implement a series of measures to stabilize oil transportation in the Persian Gulf, and hence oil prices fell for the first time since the Iran conflict on Wednesday, leading to a decline in oil stocks, with Chevron (CVX.US) and ExxonMobil (XOM.US) each dropping over 1%.
~



AASTOCKS Financial News
Website: www.aastocks.com

Nvidia (NVDA.US)'s recent USD30 billion investment in OpenAI might be its last investment in this startup, said Jensen Huang, Nvidia's CEO.

Huang also added that the opportunity to invest USD100 billion in OpenAI is unlikely to materialize, as it may soon go public.
~



AAStocks Financial News
Web Site: www.aastocks.com

BARCELONA, Spain, March 4, 2026 /PRNewswire/ -- nubia unveiled its revolutionary nubia Neo 5 series at MWC Barcelona 2026, led by nubia Neo 5 GT - the only device in its class featuring a built-in fan and a completely flat design, alongside the more accessible nubia Neo 5 and nubia Neo 5 Max boasting a 7.5-inch large display. Aiming to provide champion-level gaming experience for young users, they pack powerful gaming capabilities including professional-grade cooling, lightning-fast triggers, marathon battery life, AI Game Space, and the exclusive AI Copilot Demi 2.0 into a sleek gaming powerhouse.

"At nubia, our vision is simple but ambitious: to become the tech brand that best resonates with lifestyles of the youth." said Bai Keke, Vice President of ZTE. "We're building a diverse product portfolio addressing every scenario of the youth's lifestyles. By combining gaming-tuned AI with pro-level esports features into a slim, accessible package, nubia Neo series is truly 'Born to Win' whether for intense battles or daily tasks."

Only Built-in Fan in its Class for Unbeatable Stability

While other phones rely only on passive cooling, nubia Neo 5 GT is the first and only device in its class to pack a real active cooling fan inside, combined with a massive 29,508mm² cooling area. This game-changer works with a specialized Through-Flow Duct Design, guiding fresh airflow directly over CPU and battery.

The device runs on the Cold-Core Trinity, composed of a MediaTek D7400 4nm efficient architecture with LPDDR Max 6400Mbps dynamic memory, managed by the NeoTurbo Engine, which intelligently optimizes resources to deliver high and stable frame rates for consistently outstanding gaming experiences. The 360° Game Antenna ensures a strong connection. nubia works closely with top game developers to jointly optimize gaming performance. nubia Neo 5 GT is officially certified for 120FPS gameplay on Garena Free Fire and MLBB. Furthermore, the device delivers an impressive 90FPS experience on the graphically intense Delta Force (compatible with the Mid-Season updated version).

Trigger Victory with Console-Level Precision

nubia Neo 5 GT features 550Hz Neo Triggers 5.0, the industry-leading sub-5.5ms latency and a 3049Hz instant touch rate, making it feels like a dedicated gaming console promising instant response and zero delay. Magic Touch 3.0 Algorithm keeps the screen responsive even when fingers are sweaty, wet, or greasy.

The 6.8-inch 1.5K AMOLED display with 144Hz refresh rate and 4,500 nits peak brightness offer sharp and smooth visuals. For long gaming sessions, SGS-certified Eye Care helps reduce eye strain, making extended play less tiring. To ensure the winning streak lasts all day, nubia Neo 5 GT packs a massive 6210mAh dual-cell battery, paired with up to 80W Super Fast Charging (45W PD for EU market). For heavy gamers, Bypass Charging directly powers the phone without charging the battery while gaming.

Immersive Gaming Experience Meets Completely Flat Design

nubia Neo 5 GT features unique ID and CMF design, marking the only flat back design in its class, eliminating the camera bump for a steady grip. This comfort is further enhanced by refined rounded corners and a specialized 90° charging cable. The phone delivers immersive audio-visual experiences through Stereo Dual Speakers with DTS:X® Ultra and a X-Axis linear motor, enhanced by Eagle Eye & Fan RGB lighting that reacts to gameplay.

The esports-level AI Game Space 5.0 puts all performance settings and game management in one place. Inside features the exclusive AI Copilot Demi 2.0, acting as both coach and companion. Gaming Coach offers real-time status updates, while Gaming Chatbot answers gameplay questions instantly, Demi Auto-Chat reads and replies to messages automatically.

nubia Neo 5 series is more than just a gaming smartphone, further boosted by the 50MP AI Triple Rear Camera, a 16MP Front Camera, and practical AI functions. nubia Neo 5 series will begin its global rollout first in Southeast Asia this March. Prices start at €399 for nubia Neo 5 GT and €299 for nubia Neo 5 - both available in three distinct colors.

For more information, please visit the ZTE booth (3F30, Hall 3, Fira Gran Via) at MWC Barcelona 2026 or explore: https://www.zte.com.cn/global/about/exhibition/mwc26.html

MEDIA INQUIRIES:
ZTE Corporation
Communications
Email: [email protected]

西班牙巴塞羅那2026年3月4日 /美通社/ -- 北京時間3月3日，在2026年世界移動通信大會（MWC26巴塞羅那）上，中興通訊終端業務旗下努比亞、紅魔品牌發布系列游戲新品，包括努比亞Neo 5系列游戲手機，紅魔11系列電競旗艦、紅魔電競平板3 Pro、紅魔游戲本16 Pro 臻金傳奇 3D探索版等電競裝備，憑借領先的產品生態與技術實力，向全球市場展現在游戲賽道的深耕成果。

中興通訊高級副總裁、終端事業部總裁倪飛表示：「『AI for All』是我們的整體戰略，游戲是我們的差異化賽道。中興通訊終端業務通過紅魔和努比亞雙品牌協同策略，打造全球年輕人喜愛的游戲生態。紅魔定義專業電競宇宙，探索性能天花板；努比亞Neo系列游戲手機承接『年輕人的第一部游戲手機』，實現頂級電競體驗的降維普及。」

努比亞Neo 5系列海外首發，三大硬核技術讓旗艦體驗觸手可及

作為努比亞在游戲賽道的重要布局，努比亞Neo系列以「Born to Win」為理念，致力於通過旗艦同源的電競基因與垂域AI構建核心競爭力。憑借出色的產品力，努比亞Neo系列2025年全年收入同比增長300%，成為年輕玩家心中的熱門之選。

此次海外首發的努比亞Neo 5 GT系列，將旗艦技術下放，帶來三大硬核技術「降維」普及。其搭載「主動風冷」系統，確保手機在長時間高負載運行下不降頻、不燙手；同檔唯一純平設計、業界首創雙肩鍵四指操控，讓手機變身自帶手柄的專業電競裝備，實現操作零失誤。

在硬核的硬件基礎之上，努比亞Neo 5 GT系列依托垂域AI深度賦能，NeoTurbo AI Engine優化游戲性能，智能調配CPU、內存和散熱資源，協同作戰，更能「穩」操勝券。在應用層通過 Demi 數字人構建差異化交互界面，數字人圍繞「教」、「陪」核心場景，提供戰術指導、陪聊互動與嘴替輸出等全維度服務，讓游戲手機從工具進化為懂用戶的數字隊友，為玩家帶來沉浸式情緒價值。

除了游戲手機產品，努比亞Neo系列還著力打造玩家生態，以游戲手機為核心支點，向外輻射散熱背夾、電競耳機、游戲手柄等電競外設矩陣，實現從「單機突圍」到「生態共贏」，為用戶打造沉浸式移動競技場AI Gaming Arena。

紅魔電競宇宙全面升級，憑借「性能天花板」鞏固全球領先地位

作為高端電競裝備品牌，紅魔（REDMAGIC）以「Win More Games」為口號，多年來，憑借卓越性能贏得全球玩家信賴，已進入超過30個國家和地區，成為全球領先的游戲手機品牌之一。2025年紅魔電競宇宙銷量增長226%，穩居全球電競手機市場份額Top 1。

旗艦游戲手機紅魔11 Pro+ 攜多項首發獨家技術強勢登場：行業首次將水冷與風冷同時應用於手機，行業首發京東方X10屏下發光材料，行業首創4D冰階VC，並首次加入IPX8防水、80W無線快充及超聲波指紋解鎖，配合7500mAh超大電池與120W魔閃快充，成就最強充電組合，在游戲玩家最關注的性能、續航、幀率方面做到行業領先，帶來了超乎想象的極致電競體驗。

面向高端電競與沉浸體驗打造的旗艦游戲本——紅魔游戲本 16 Pro「GOLDEN SAGA•3D探索版」，在設計中首次融入「流金水冷」設計，搭載英特爾酷睿Ultra9處理器與英偉達RTX 5090顯卡和突破性的4K裸眼3D顯示屏，配合Magic Vision引擎，為玩家帶來裸眼3D游戲體驗，貫穿機身的RGB燈效更是為玩家提供豐富的炫彩電競氛圍。

在電競平板領域，紅魔電競平板3 Pro順應市場需求，以更小的9.06英寸身形，搭載驍龍8至尊版移動平台與內置離心風扇的PAD魔冷散熱系統3.0，配置8200mAh+80W快充等，提供更強悍的電競體驗。此外，本次MWC紅魔也透露了下一代小平板紅魔電競平板5 Pro即將發布，它具備更強的性能，為玩家帶來更出色的游戲體驗，敬請期待。

游戲是年輕人表達自我、連接世界的重要方式。中興通訊終端業務通過「雙品牌協同」與「技術下放」，讓頂級電競體驗觸手可及。未來，中興通訊將持續探索AI與電競的深度融合，以硬科技賦能創新，以軟文化連接情感，為全球Z世代構建更開放、更智能的游戲生態。

媒體聯絡：
ZTE Corporation
Communications
Email: [email protected]

• Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer
• Novel combination therapy will be studied as part of the Phase II adaptive platform trial known as the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), sponsored by the Dana-Farber Cancer Institute
• Study builds on the previously reported positive Phase II results involving INO-5401 in GBM, adding a novel, first-in-class PD-1/CTLA-4 bi-specific immunotherapy, which potentially provides additional checkpoint inhibition through CTLA-4 binding.

HONG KONG and PLYMOUTH MEETING, Pa., March 4, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), and INOVIO (NASDAQ: INO) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with INO-5412, INOVIO's DNA immunotherapy candidate, for the potential treatment of GBM. The combination therapy will be studied as a part of INSIGhT, the innovative Phase II adaptive platform trial sponsored by the Dana-Farber Cancer Institute and conducted with Mass General Brigham Cancer Care, Inc., which is designed to quickly and efficiently find new treatments for GBM. Dosing in the combination therapy trial is expected to begin in the second half of 2026.

Cadonilimab has received marketing approval in China for several indications, including first-line gastric cancer, first-line cervical cancer, and second/third-line cervical cancer, demonstrating effectiveness irrespective of PD-L1 expression status. As the world's first approved bispecific antibody for cancer immunotherapy, cadonilimab has established its clinical value through real-world application and validation across multiple Phase III trials. The drug is currently involved in over 11 Phase III/registration clinical studies including global programs such as a Phase III registrational trial for the first-line treatment of gastric cancer, and a Phase II registrational trial for the second-line treatment of liver cancer in patients who exhibit resistance to immune checkpoint inhibitors (IO).

INO-5412 is composed of INO-5401 and T cell immune activator INO-9012. When combined with a checkpoint blockade, targeted DNA immunotherapy has the potential to overcome the challenges of immune checkpoint therapy alone by stimulating an immune response against tumor antigens and driving T cell infiltration into the glioblastoma tumor microenvironment. In an ongoing Phase II trial in newly diagnosed GBM patients, INO-5401 plus INO-9012 in combination with a PD-1 checkpoint inhibitor elicited robust immune responses that potentially correlate with enhanced survival. The novel combination of INO-5412 with cadonilimab to treat GBM builds on this promising data and could potentially benefit patients by providing additional checkpoint inhibition through CTLA-4 binding.

Dr. David Reardon, Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute and a professor at Harvard Medical School said, "The INSIGhT trial was designed to help quickly advance cutting-edge treatments for GBM, the most common and aggressive form of brain cancer for which there are few effective treatments currently available or in development. We are excited to include INOVIO and Akeso's novel combination immunotherapy in the trial and welcome their efforts to help improve potential outcomes for patients."

Yu (Michelle) Xia, PhD, founder, chairwoman, president, and Chief Executive Officer of Akeso, said, "We are truly excited to collaborate with INOVIO for the treatment of GBM. We are advancing cadonilimab worldwide through Akeso's 'in-house innovation + global partnership' strategy to realize its breakthrough clinical benefits for patients all around the world across multiple cancer types. By collaborating with INOVIO, we aim to harness the benefit of combining INOVIO's DNA medicine with cadonilimab's dual checkpoint inhibition for the treatment of GBM, a particularly challenging central nervous system malignancy. We also look forward to working with one of the world's leading cancer centers in the clinical development of the new cadonilimab and INO-5412 combination treatment for GBM."

Dr. Michael Sumner, INOVIO's Chief Medical Officer, said, "This collaboration is an important step forward for our cancer immunotherapy research and we are delighted to partner with two trailblazing organizations to advance this promising candidate in our late-stage clinical pipeline. Combining INO-5412 with Akeso's novel checkpoint modality represents an important evolution of our research in GBM, builds on our previous data showing the potential to improve patient outcomes and highlights our ongoing commitment to advancing innovative treatments for diseases with significant unmet need."

Under the terms of the agreement, INOVIO and Akeso will provide support for the INSIGhT study, including supplying their respective therapeutic products, while the investigative sponsors will oversee the day-to-day clinical operations.

About Cadonilimab
Cadonilimab, independently developed by Akeso, is the world's first PD-1/CTLA-4 bispecific immuno-oncology therapy. It has been approved and reimbursed in China for three indications: recurrent/metastatic cervical cancer after platinum-based chemotherapy failure, first-line gastric cancer, and first-line cervical cancer. The drug has also been investigated in over 30 clinical trials spanning more than 20 tumor types. Currently, 11 Phase III or registrational trials are ongoing, with three already having met primary endpoints. With a novel dual-targeting mechanism against PD-1 and CTLA-4, cadonilimab demonstrates superior efficacy and a favorable safety profile compared to combination therapies. It has shown strong anti-tumor activity regardless of PD-L1 status and holds breakthrough potential in IO-resistant and immunologically "cold" tumors.

About INO-5412
INO-5412 is an investigational DNA medicine that combines INO-5401 and INO-9012 into a single vial as a potentially powerful cancer immunotherapy particularly when given in combination with checkpoint inhibitors. INO-5401 plus INO-9012 has been previously investigated as a potential therapeutic treatment targeting a number of cancers, including GBM and cancers exhibiting BRCA1 and BRCA2 mutations. Data from an ongoing Phase II trial in newly diagnosed GBM patients, highlighted in a 2022 oral presentation at the American Society of Clinical Oncology (ASCO), demonstrated that INO-5401 plus INO-9012 in combination with a PD-1 checkpoint inhibitor elicited robust immune responses that potentially correlated with enhanced survival. (Reardon D. et al, ASCO 2022).

INO-5401 encodes for INOVIO's SynCon® antigens for hTERT, WT1, and PSMA, which are antigens The National Cancer Institute has highlighted as important targets and designated as high priorities for cancer immunotherapy development. These three antigens have been reported to be over-expressed and often mutated in a variety of human cancers, including GBM. INO-9012 encodes for IL-12, which is a T cell immune activator. 

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

About INOVIO's DNA Medicines Platform
INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.

Akeso Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

INOVIO Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including INOVIO's planned clinical collaboration with Akeso to advance novel combination therapy for GBM, plans for the combination therapy to be studied as part of INSIGhT, the expected timing for dosing in the combination therapy trial to begin in the second half of 2026, as well as the potential benefits of INO-5412 in combination with a checkpoint inhibitor such as cadonilimab. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.